INmune Bio Inc.

$INMB is getting crushed today after its experimental Alzheimer’s drug XPro failed to improve cognitive functions in patients with early stages of the disease in a mid-stage study. On top of that as mentioned on Friday, the company announced a direct stock offering.  Shares are currently at an all-time low.

Share this article:

About the Author:

INmune Bio Inc.

Joey Ramson

PRISM Market View Alerts

Get your dose of PRISM Market
View news, right in your inbox

Mailchimp Signup